JFM, your posted article takes about 30 minutes to read but is well worth the invested time to better understand not only the challenges of pandemics but most importantly the required solutions to the problem. When you read what the author’s suggested solutions are, the answer lies within the uniqueness of Brilacidin being one of the best drug candidates capable of attacking and destroying SARS-CoV-2 variants and other coronaviruses, while mitigating or averting the threat of drug resistance developing.
===================================================
Solutions:

“Mass antiviral treatment with whatever drug that effectively reduces viral infectious pressure.”

“Early treatment of people showing first sign and symptoms will result in enhanced rates of recovery from disease and, therefore, raise the number of people who develop life-long protective immunity against the viral variant they got infected with as well as against a diversified spectrum of other, more infectious circulating variants. Enhanced recovery rates will, therefore, contribute to building herd immunity (HI).”

“A durable control of the pandemic will, therefore, ultimately require an immune intervention that is able to prevent infection in all age groups that are naturally susceptible to Covid-19 disease (those are likely to include some age groups < 65 years due to the high level of innate immune suppression exerted by highly infectious circulating variants). As long as such an immune intervention is not available, antiviral chemoprophylaxis may need to be repeated at regular intervals.”

“However, antiviral chemoprophylaxis should not be considered a long-term strategy since overuse of any antiviral compound could potentially promote viral resistance to it. “ (NOTE: This is an important key differentiating advantage that Brilacidin has over other antiviral drugs.)